Autopsy report · NCT02242656
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals
Cause of deathRegulatory or ethics
“Transfer of IND to new marketing authorization holder”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- Marathon Pharmaceuticals, LLC
- Sponsor type
- Industry
- Conditions
- Short Bowel Syndrome; Short Gut Syndrome; SBS; Short Bowel; Short Gut
- Interventions
- Opium Tincture USP Deodorized; Opium Tincture USP Deodorized
- Participants
- 0
- Sites
- 5
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.